Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro

Int J Antimicrob Agents. 2001 Aug;18(2):107-12. doi: 10.1016/s0924-8579(01)00366-1.

Abstract

A sparfloxacin-susceptible clinical isolate of Staphylococcus aureus was grown in increased concentrations of sparfoxacin. The presence of mutations in gyrA, gyrB, grlA and grlB genes was analyzed. The primary point mutation was located in the gyrA gene (Glu-88 to Lys). Two further mutation steps appeared in the amino acid change Ser-80 to Tyr in GrlA. No mutations occurred in the gyrB or grlB genes. Efflux pumps involved in the increase of resistance were also found to affect norfloxacin and ciprofloxacin. This effect may be related to NorA. An overexpression of NorA, may be associated with the increase of the MIC of norfloxacin from 32 mg/l to >200 mg/l in the final mutant. The MICs levels of sparfloxacin were affected by unknown mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Bacterial Proteins / genetics
  • DNA Gyrase / genetics*
  • DNA Topoisomerase IV / genetics*
  • Drug Resistance, Bacterial / genetics
  • Fluoroquinolones*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Multidrug Resistance-Associated Proteins
  • Point Mutation*
  • Sequence Analysis, DNA
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / enzymology
  • Staphylococcus aureus / genetics
  • Staphylococcus aureus / growth & development

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • Fluoroquinolones
  • Multidrug Resistance-Associated Proteins
  • NorA protein, Staphylococcus
  • DNA Topoisomerase IV
  • DNA Gyrase
  • sparfloxacin